Tech Company Financing Transactions

Syntimmune Funding Round

Syntimmune secured a $8 million Series A funding round on 11/21/2016. Backers included Apple Tree Partners, Baxalta Ventures and Partners Innovation Fund.

Transaction Overview

Company Information

Company Status

Acquired or Merged

Industry

Biopharmaceutical

Mailing Address

116 Huntington Ave. 301
Boston, MA 02116
USA

Phone

617-206-4220

Website

www.syntimmune.com

Email Address

[email protected]

Overview

Founded in 2013, Syntimmune is the world's leader in the biology of the neonatal Fc receptor (FcRn). Helmed by the most recognized experts in its field, Syntimmune is positioned to rapidly advance breakthrough therapies which co-opt this unique target.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jean Kress

        

Chief Financial Officer

John McBride

        

Chief Medical Officer

Mario Saltarelli

        

Vice President

Stephanie Haller

        

Vice President

Nicole Luosey

        

VP - Operations

Adam Hansard

        

VP - Regulatory Affairs

Donald Johns

        

VP - Regulatory Affairs

Leslie Stolz

        

Browse more venture capital transactions:

Prev: 11/21/2016: Garmentory venture capital transaction
Next: 11/21/2016: Bitmark venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary